Related Experiment Video

Updated: Jun 6, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K

TTK promotes HER2 + breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the

Shaolin Zhang1,2, Hua Ding3, Yongfen Deng4

  • 1Department of Clinical Medicine, Guizhou Medical University, Guiyang, China.

Journal of Cancer Research and Clinical Oncology
|November 26, 2024
PubMed
Abstract

Insights

The TTK gene promotes aggressive HER2-positive breast cancer growth and migration. Inhibiting TTK in HER2-positive breast cancer enhances sensitivity to targeted therapies like pyrotinib.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • HER2-positive breast cancer (BRCA) is aggressive and challenging to treat.
  • The role of the TTK gene in HER2-positive BRCA is not well understood.
  • TTK is increasingly linked to various tumor types.

Purpose of the Study:

  • To investigate the biological function of the TTK gene in HER2-positive BRCA.
  • To understand TTK's role in resistance to targeted therapies.
  • To identify new therapeutic targets for HER2-positive BRCA.

Main Methods:

  • Small interfering RNA (siRNA) was used to knock down TTK expression in HER2-positive BRCA cells.
  • Cell proliferation and migration were assessed.
  • Mechanism of action was analyzed using RT-PCR and Western blot.

Main Results:

  • TTK knockdown inhibited cell proliferation and migration in HER2-positive BRCA.
  • TTK activates the Akt/mTOR pathway, promoting cancer progression.
  • Knockdown of TTK induced apoptosis and G1 cell cycle arrest.
  • TTK inhibition increased sensitivity to pyrotinib in BRCA cell lines (SKBR3, BT474).

Conclusions:

  • TTK functions as an oncogene in HER2-positive breast cancer.
  • TTK is a potential therapeutic target for HER2-positive BRCA.
  • Targeting TTK may overcome resistance to targeted therapies.
Keywords:
ApoptosisDrug resistanceHER2 + breast cancerIgrationTarget

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.8K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.3K